Donatella Marino

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Masatoshi Kudo, Tim Meyer et al. · JAMA Oncology · 2023 · 249 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer

Srinivasa R. Rao, Ann E. Snaith, Donatella Marino et al. · British Journal of Cancer · 2016 · 189 citations · Full text

Medicine, Cancer Biology, Oncology +17

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type <scp><i>KRAS</i></scp> advanced biliary tract cancer: A randomized phase 2 trial (<scp>V</scp>ecti‐<scp>BIL</scp> study)

Francesco Leone, Donatella Marino, Stefano Cereda et al. · Cancer · 2015 · 140 citations · Full text

Medicine, Oncology, Pharmacology +13

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Shukui Qin, Masashi Kudo, T Meyer et al. · Annals of Oncology · 2022 · 66 citations · Full text

Medicine, Oncology, Pharmacology +13

The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life

Chiara Baratelli, Carmela Giovanna Cleopatra Turco, Gaetano Lacidogna et al. · Supportive Care in Cancer · 2019 · 31 citations

Pharmacy, Oncology, Medical Oncology +14